Karl Eckert

934 total citations
19 papers, 581 citations indexed

About

Karl Eckert is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Karl Eckert has authored 19 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Karl Eckert's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Karl Eckert is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Karl Eckert collaborates with scholars based in United States, Australia and Belgium. Karl Eckert's co-authors include Dongping He, Brent T. Harris, Ann Tsukamoto, Nobuko Uchida, Sunil Jain, Robert Tushinski, Irving L. Weissman, Michael J. Reitsma, Richard E. Sutton and Stanley Tamaki and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Virology.

In The Last Decade

Karl Eckert

19 papers receiving 576 citations

Peers

Karl Eckert
Bénédicte Hivert France
Romain Daveau France
Craig Soderquist United States
Valerie Eaton United States
Deepa Deshpande United States
Laurent Drouot France
R Espinosa United States
Daniel Rosebrock United States
Tenley C. Archer United States
Bénédicte Hivert France
Karl Eckert
Citations per year, relative to Karl Eckert Karl Eckert (= 1×) peers Bénédicte Hivert

Countries citing papers authored by Karl Eckert

Since Specialization
Citations

This map shows the geographic impact of Karl Eckert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Eckert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Eckert more than expected).

Fields of papers citing papers by Karl Eckert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Eckert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Eckert. The network helps show where Karl Eckert may publish in the future.

Co-authorship network of co-authors of Karl Eckert

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Eckert. A scholar is included among the top collaborators of Karl Eckert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Eckert. Karl Eckert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Jain, Nitin, Lisa J. Croner, John N. Allan, et al.. (2023). Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical Cancer Research. 30(3). 498–505. 20 indexed citations
2.
Eckert, Karl, et al.. (2022). Resource Management as Part of Sustainable Urban District Development. Sustainability. 14(7). 4224–4224. 6 indexed citations
3.
4.
Wang, Michael, Radhakrishnan Ramchandren, Robert Chen, et al.. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology & Oncology. 14(1). 179–179. 39 indexed citations
5.
Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2020). The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma. British Journal of Haematology. 189(4). 650–660. 20 indexed citations
6.
Tam, Constantine S., Radhakrishnan Ramchandren, Robert Chen, et al.. (2020). Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study. Blood. 136(Supplement 1). 39–41. 5 indexed citations
7.
Wang, Michael, Wojciech Jurczak, Karl Eckert, et al.. (2020). MCL-129: First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study. Clinical Lymphoma Myeloma & Leukemia. 20. S259–S259. 1 indexed citations
8.
9.
Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512. 32 indexed citations
10.
Wierda, William G., Tanya Siddiqi, Ian W. Flinn, et al.. (2018). Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 36(15_suppl). 7502–7502. 20 indexed citations
11.
Kuo, Hsu-Ping, Scott A. Ezell, Karl J. Schweighofer, et al.. (2017). Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Molecular Cancer Therapeutics. 16(7). 1246–1256. 45 indexed citations
12.
Ghia, Paolo, Constantine S. Tam, Tanya Siddiqi, et al.. (2017). AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL. Hematological Oncology. 35(S2). 428–428. 1 indexed citations
13.
Kuo, Hsu-Ping, Scott A. Ezell, Karl J. Schweighofer, et al.. (2016). The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.. PubMed. 6(11). 2489–2501. 37 indexed citations
14.
Kuo, Hsu-Ping, Karl J. Schweighofer, Leo W.K. Cheung, et al.. (2015). The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Blood. 126(23). 699–699. 39 indexed citations
15.
Kuo, Hsu-Ping, R. Webster Crowley, Ling Xue, et al.. (2014). Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma. Blood. 124(21). 505–505. 7 indexed citations
16.
Chang, Betty, Richard R. Furman, Marc Zapatka, et al.. (2013). Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7014–7014. 30 indexed citations
17.
Eckert, Karl. (2009). Garden Cities: Lessons from Germany. DigitalCommons - CalPoly (California State Polytechnic University). 6(1). 1 indexed citations
18.
Tamaki, Stanley, Karl Eckert, Dongping He, et al.. (2002). Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. Journal of Neuroscience Research. 69(6). 976–986. 186 indexed citations
19.
Berkowitz, Robert D., Heini Ilves, WeiYu Lin, et al.. (2001). Construction and Molecular Analysis of Gene Transfer Systems Derived from Bovine Immunodeficiency Virus. Journal of Virology. 75(7). 3371–3382. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bénédicte Hivert Breakdown of academic impact, for papers by Romain Daveau Breakdown of academic impact, for papers by Craig Soderquist Breakdown of academic impact, for papers by Valerie Eaton Breakdown of academic impact, for papers by Deepa Deshpande Breakdown of academic impact, for papers by Laurent Drouot Breakdown of academic impact, for papers by R Espinosa Breakdown of academic impact, for papers by Daniel Rosebrock Breakdown of academic impact, for papers by Tenley C. Archer
Rankless by CCL
2026